Nintedanib Esylate (BioDeep_00000685001)
代谢物信息卡片
Nintedanib Ethanesulfonate Salt
化学式: C33H39N5O7S (649.257)
中文名称: 尼达尼布乙基磺酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O
InChI: 2H2,1H3,(H,3,4,5)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D000970 - Antineoplastic Agents
同义名列表
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Rajwinder Kaur, Taslim B Shaikh, Hari Priya Sripadi, Madhusudana Kuncha, U V R Vijaya Sarathi, Hitesh Kulhari, Sai Balaji Andugulapati, Ramakrishna Sistla. Nintedanib solid lipid nanoparticles improve oral bioavailability and ameliorate pulmonary fibrosis in vitro and in vivo models.
International journal of pharmaceutics.
2024 Jan; 649(?):123644. doi:
10.1016/j.ijpharm.2023.123644. [PMID: 38040396] - Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Journal of experimental & clinical cancer research : CR.
2022 Jul; 41(1):217. doi:
10.1186/s13046-022-02423-0. [PMID: 35794623] - G D Marijn Veerman, Sanne C van der Werff, Stijn L W Koolen, Jelle R Miedema, Esther Oomen-de Hoop, Sophie C van der Mark, Prewesh P Chandoesing, Peter de Bruijn, Marlies S Wijsenbeek, Ron H J Mathijssen. The influence of green tea extract on nintedanib's bioavailability in patients with pulmonary fibrosis.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Jul; 151(?):113101. doi:
10.1016/j.biopha.2022.113101. [PMID: 35594703] - Jay Kataria, Jack Kerr, Sandra R Lourenssen, Michael G Blennerhassett. Nintedanib regulates intestinal smooth muscle hyperplasia and phenotype in vitro and in TNBS colitis in vivo.
Scientific reports.
2022 Jun; 12(1):10275. doi:
10.1038/s41598-022-14491-5. [PMID: 35715562] - Anuraag Jena, Tanushi Aggarwal, Suvradeep Mitra, Anupam Kumar Singh. Nintedanib-induced liver injury: Not every liver injury is virus or vaccine-induced in the era of COVID-19.
Liver international : official journal of the International Association for the Study of the Liver.
2022 05; 42(5):1210-1211. doi:
10.1111/liv.15206. [PMID: 35195327] - Chuankun Wang, Lizhe Qu. The anti-fibrotic agent nintedanib protects chondrocytes against tumor necrosis factor-ɑ (TNF-ɑ)-induced extracellular matrix degradation.
Bioengineered.
2022 03; 13(3):5318-5329. doi:
10.1080/21655979.2022.2036899. [PMID: 35164664] - Madelon C Vonk, Alfredo Guillén-Del-Castillo, Michael Kreuter, Mandy Avis, Kristell Marzin, Salome R Mack, Sven Wind, Martina Gahlemann. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
European journal of drug metabolism and pharmacokinetics.
2022 Jan; 47(1):81-89. doi:
10.1007/s13318-021-00728-7. [PMID: 34664183] - Giacomo Sgalla, Alessia Comes, Marialessia Lerede, Luca Richeldi. COVID-related fibrosis: insights into potential drug targets.
Expert opinion on investigational drugs.
2021 Dec; 30(12):1183-1195. doi:
10.1080/13543784.2021.2010188. [PMID: 34842488] - Varalakshmi Velagacherla, Akhil Suresh, Chetan H Mehta, Usha Y Nayak. Advances and challenges in nintedanib drug delivery.
Expert opinion on drug delivery.
2021 11; 18(11):1687-1706. doi:
10.1080/17425247.2021.1985460. [PMID: 34556001] - Ying Xu, Yulong Liu, Taofeng He, Yaqi Zhang, Mingyun Wang, Huaqin Yuan, Mi Yang. Biguanides decorated albumin nanoparticles loading nintedanib for synergic enhanced hepatocellular carcinoma therapy.
Colloids and surfaces. B, Biointerfaces.
2021 Nov; 207(?):112020. doi:
10.1016/j.colsurfb.2021.112020. [PMID: 34403984] - Abeda Jamadar, Sreenath M Suma, Sijo Mathew, Timothy A Fields, Darren P Wallace, James P Calvet, Reena Rao. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Cell death & disease.
2021 10; 12(10):947. doi:
10.1038/s41419-021-04248-9. [PMID: 34650051] - Hai Zou, Sheng-Qing Li. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
Acta pharmacologica Sinica.
2021 08; 42(8):1376-1378. doi:
10.1038/s41401-020-00566-4. [PMID: 33188277] - Ulrike Schmid, Benjamin Weber, Celine Sarr, Matthias Freiwald. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
BMC pulmonary medicine.
2021 Jul; 21(1):244. doi:
10.1186/s12890-021-01598-0. [PMID: 34289823] - Yutaka Umemura, Yumi Mitsuyama, Kensuke Minami, Takeshi Nishida, Atsushi Watanabe, Naoki Okada, Kazuma Yamakawa, Kotaro Nochioka, Satoshi Fujimi. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2021 Jul; 108(?):454-460. doi:
10.1016/j.ijid.2021.05.055. [PMID: 34048887] - Tang-Hsiu Huang, Chin-Wei Kuo, Chian-Wei Chen, Yau-Lin Tseng, Chao-Liang Wu, Sheng-Hsiang Lin. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
BMC pulmonary medicine.
2021 May; 21(1):165. doi:
10.1186/s12890-021-01530-6. [PMID: 33992083] - Elia Bari, Ilaria Ferrarotti, Laura Saracino, Sara Perteghella, Maria Luisa Torre, Luca Richeldi, Angelo Guido Corsico. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?.
Cells.
2021 05; 10(5):. doi:
10.3390/cells10051203. [PMID: 34068958] - Laura Bergantini, Miriana d'Alessandro, Paolo Cameli, Alfonso Carleo, Claudia Landi, Lucia Vietri, Nicola Lanzarone, Maria Pieroni, Piersante Sestini, Elena Bargagli. Antithrombin III as predictive indicator of survival in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib: a preliminary study.
Internal medicine journal.
2021 May; 51(5):705-711. doi:
10.1111/imj.14768. [PMID: 32040256] - Priyanshi Patel, Mitali Patel. Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Apr; 159(?):105715. doi:
10.1016/j.ejps.2021.105715. [PMID: 33453388] - Ulrike Schmid, Benjamin Weber, Mats O Magnusson, Matthias Freiwald. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Respiratory medicine.
2021 Apr; 180(?):106369. doi:
10.1016/j.rmed.2021.106369. [PMID: 33798871] - Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, Sabine Tejpar, Fortunato Ciardiello, Jürgen Braunger, Alexey V Salnikov, Ogsen Gabrielyan, Ramona Schmid, Josef Höfler, Thomas Kitzing, Eric Van Cutsem. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Clinical colorectal cancer.
2021 03; 20(1):84-95.e8. doi:
10.1016/j.clcc.2020.09.003. [PMID: 33041226] - Chi Zhang, Zhao Wu, Jia-Wen Li, Kangan Tan, Wanna Yang, Hong Zhao, Gui-Qiang Wang. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
Journal of medical virology.
2021 03; 93(3):1378-1386. doi:
10.1002/jmv.26634. [PMID: 33107641] - G D Marijn Veerman, Peter de Bruijn, Anne-Marie C Dingemans, Ron H J Mathijssen, Stijn L W Koolen. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2021 Jan; 193(?):113733. doi:
10.1016/j.jpba.2020.113733. [PMID: 33217707] - Huachun Cui, Na Xie, Sami Banerjee, Jing Ge, Dingyuan Jiang, Tapan Dey, Qiana L Matthews, Rui-Ming Liu, Gang Liu. Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.
American journal of respiratory cell and molecular biology.
2021 01; 64(1):115-125. doi:
10.1165/rcmb.2020-0360oc. [PMID: 33074715] - Vikas Marwah, Robin Choudhary, Virender Malik, Arpita Pemmaraju, Deepu Peter. Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series.
Advances in respiratory medicine.
2021; 89(6):589-596. doi:
10.5603/arm.a2021.0113. [PMID: 34966994] - Grzegorz Grześk, Anita Woźniak-Wiśniewska, Jan Błażejewski, Bartosz Górny, Łukasz Wołowiec, Daniel Rogowicz, Alicja Nowaczyk. The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications.
International journal of molecular sciences.
2020 Dec; 22(1):. doi:
10.3390/ijms22010282. [PMID: 33396592] - Shristy S Tiwari, Vivek Dhiman, Sumit Mukesh, Abhay T Sangamwar, Ragampeta Srinivas, M V N Kumar Talluri. Identification and characterization of novel metabolites of nintedanib by ultra-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry with in silico toxicological assessment.
Rapid communications in mass spectrometry : RCM.
2020 Nov; 34(22):e8915. doi:
10.1002/rcm.8915. [PMID: 32761944] - Masataka Hasegawa, Atsuko Uehara, Tomo Suzuki, Reio Sekine, Masahiko Yazawa, Daisuke Ichikawa, Junki Koike, Yugo Shibagaki. Nintedanib-induced glomerular microangiopathy: a case report.
CEN case reports.
2020 11; 9(4):295-300. doi:
10.1007/s13730-020-00474-w. [PMID: 32279192] - Ayodeji Adegunsoye, Shehabaldin Alqalyoobi, Angela Linderholm, Willis S Bowman, Cathryn T Lee, Janelle Vu Pugashetti, Nandini Sarma, Shwu-Fan Ma, Angela Haczku, Anne Sperling, Mary E Strek, Imre Noth, Justin M Oldham. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Chest.
2020 10; 158(4):1526-1534. doi:
10.1016/j.chest.2020.04.066. [PMID: 32450241] - Robert W Simms. Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma.
Arthritis & rheumatology (Hoboken, N.J.).
2020 09; 72(9):1415-1426. doi:
10.1002/art.41406. [PMID: 32562363] - Yunjing Zhu, Xue Liang, Cong Lu, Yihan Kong, Xing Tang, Yu Zhang, Tian Yin, Jingxin Gou, Yanjiao Wang, Haibing He. Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption.
International journal of pharmaceutics.
2020 Aug; 586(?):119569. doi:
10.1016/j.ijpharm.2020.119569. [PMID: 32592899] - Gali Epstein-Shochet, Stephen Pham, Steven Beck, Safaa Naiel, Olivia Mekhael, Spencer Revill, Aaron Hayat, Megan Vierhout, Becky Bardestein-Wald, David Shitrit, Kjetil Ask, A Bruce Montgomery, Martin R Kolb, Mark W Surber. Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship.
Pulmonary pharmacology & therapeutics.
2020 08; 63(?):101933. doi:
10.1016/j.pupt.2020.101933. [PMID: 32750409] - Mark W Surber, Steve Beck, Stephen Pham, Angela T Marsden, Senthil K Gandi, James Baily, Mary C McElroy. Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis.
Pulmonary pharmacology & therapeutics.
2020 08; 63(?):101938. doi:
10.1016/j.pupt.2020.101938. [PMID: 32841676] - Claudia Landi, Laura Bergantini, Paolo Cameli, Miriana d'Alessandro, Alfonso Carleo, Enxhi Shaba, Paola Rottoli, Luca Bini, Elena Bargagli. Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy.
Scientific reports.
2020 06; 10(1):9378. doi:
10.1038/s41598-020-66296-z. [PMID: 32523095] - Sebastiano Emanuele Torrisi, Nicolas Kahn, Carlo Vancheri, Michael Kreuter. Evolution and treatment of idiopathic pulmonary fibrosis.
Presse medicale (Paris, France : 1983).
2020 Jun; 49(2):104025. doi:
10.1016/j.lpm.2020.104025. [PMID: 32437841] - Heidrun L Deissler, Jan-Niklas Stutzer, Gerhard K Lang, Salvatore Grisanti, Gabriele E Lang, Mahdy Ranjbar. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A165-induced disturbances of barriers formed by retinal endothelial cells or long-term cultivated ARPE-19 cells.
Experimental eye research.
2020 05; 194(?):108004. doi:
10.1016/j.exer.2020.108004. [PMID: 32184103] - Min-Jeong Heo, Chanmi Lee, Soo Young Choi, Yeong Min Choi, In-Sook An, Seunghee Bae, Sungkwan An, Jin Hyuk Jung. Nintedanib ameliorates animal model of dermatitis.
Scientific reports.
2020 03; 10(1):4493. doi:
10.1038/s41598-020-61424-1. [PMID: 32161331] - Zi-Meng Zhou, Yi-Kun Wang, Dong-Mei Yan, Jian-He Fang, Xue-Rong Xiao, Ting Zhang, Yan Cheng, Kang-Ping Xu, Fei Li. Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics.
Journal of pharmaceutical and biomedical analysis.
2020 Feb; 180(?):113045. doi:
10.1016/j.jpba.2019.113045. [PMID: 31887668] - Snehal K Shukla, Hossam Kadry, Jayshil A Bhatt, Rasha Elbatanony, Fakhrul Ahsan, Vivek Gupta. Statistical optimization and validation of a novel ultra-performance liquid chromatography method for estimation of nintedanib in rat and human plasma.
Bioanalysis.
2020 Feb; 12(3):159-174. doi:
10.4155/bio-2019-0284. [PMID: 32052636] - Takumi Yoshikawa, Mitsuo Otsuka, Hirofumi Chiba, Kimiyuki Ikeda, Yuki Mori, Yasuaki Umeda, Hirotaka Nishikiori, Koji Kuronuma, Hiroki Takahashi. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
BMC pulmonary medicine.
2020 Jan; 20(1):27. doi:
10.1186/s12890-020-1060-y. [PMID: 32005219] - Emilia Bigaeva, Elisabeth G D Stribos, Henricus A M Mutsaers, Bram Piersma, Anna M Leliveld, Igle J de Jong, Ruud A Bank, Marc A Seelen, Harry van Goor, Lutz Wollin, Peter Olinga, Miriam Boersema. Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis.
American journal of physiology. Renal physiology.
2020 01; 318(1):F117-F134. doi:
10.1152/ajprenal.00108.2019. [PMID: 31736352] - Lutz Wollin, Dieudonnée Togbe, Bernhard Ryffel. Effects of Nintedanib in an Animal Model of Liver Fibrosis.
BioMed research international.
2020; 2020(?):3867198. doi:
10.1155/2020/3867198. [PMID: 32337244] - Daisuke Inoue, Hiroshi Nishi, Kenjiro Honda, Taisuke Ishii, Hiroyuki Abe, Masaaki Sato, Masaomi Nangaku. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
Clinical nephrology.
2020 Jan; 93(1):47-50. doi:
10.5414/cn109900. [PMID: 31699213] - Porntipa Korprasertthaworn, Nuy Chau, Pramod C Nair, Andrew Rowland, John O Miners. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202.
Biochemical pharmacology.
2019 11; 169(?):113616. doi:
10.1016/j.bcp.2019.08.018. [PMID: 31445021] - Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser, Carl Coeck, Emmanuelle Clerisme-Beaty, Bernd Rosenstock, Manuel Quaresma, Thomas Haeufel, Rainer-Georg Goeldner, Rozsa Schlenker-Herceg, Kevin K Brown. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
The New England journal of medicine.
2019 10; 381(18):1718-1727. doi:
10.1056/nejmoa1908681. [PMID: 31566307] - Sven Wind, Ulrike Schmid, Matthias Freiwald, Kristell Marzin, Ralf Lotz, Thomas Ebner, Peter Stopfer, Claudia Dallinger. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Clinical pharmacokinetics.
2019 09; 58(9):1131-1147. doi:
10.1007/s40262-019-00766-0. [PMID: 31016670] - Young-Suk Kim, Hyunju Cha, Hyo-Jin Kim, Joong-Myung Cho, Hak-Ryul Kim. The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
Molecules (Basel, Switzerland).
2019 Jul; 24(15):. doi:
10.3390/molecules24152792. [PMID: 31370295] - Warinda Susutlertpanya, Hirokazu Wakuda, Naoyuki Otani, Takuya Kuramoto, Li Li, Masae Kuranari, Ai Sekiguchi, Hideo Kudo, Tomohisa Uchida, Hiromitsu Imai, Naoto Uemura. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Life sciences.
2019 Jul; 228(?):251-257. doi:
10.1016/j.lfs.2019.05.014. [PMID: 31078545] - Li-Jian Pang, Jian-Ping Liu, Xiao-Dong Lv. Comparative effectiveness of 3 Traditional Chinese Medicine treatment methods for idiopathic pulmonary fibrosis: A systematic review and network meta-analysis protocol.
Medicine.
2019 Jul; 98(30):e16325. doi:
10.1097/md.0000000000016325. [PMID: 31348231] - Feng Liu, George Bayliss, Shougang Zhuang. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Clinical science (London, England : 1979).
2019 06; 133(12):1309-1320. doi:
10.1042/cs20190249. [PMID: 31217321] - Angeles Alvarez Secord, Michael McCollum, Brittany A Davidson, Gloria Broadwater, Robert Squatrito, Laura J Havrilesky, Anne C Gabel, Mark D Starr, J Chris Brady, Andrew B Nixon, Linda R Duska. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Gynecologic oncology.
2019 06; 153(3):555-561. doi:
10.1016/j.ygyno.2019.03.246. [PMID: 30929823] - Miguel Quintela-Fandino, Juan V Apala, Diego Malon, Silvana Mouron, Javier Hornedo, Lucia Gonzalez-Cortijo, Ramon Colomer, Juan Guerra. Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Breast cancer research : BCR.
2019 05; 21(1):69. doi:
10.1186/s13058-019-1152-x. [PMID: 31126332] - Akiko Nakano, Hirotsugu Ohkubo, Kensuke Fukumitsu, Satoshi Fukuda, Yoshihiro Kanemitsu, Masaya Takemura, Ken Maeno, Yutaka Ito, Tetsuya Oguri, Akio Niimi. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Internal medicine (Tokyo, Japan).
2019 Apr; 58(8):1141-1144. doi:
10.2169/internalmedicine.1890-18. [PMID: 30568147] - Ravi Paluri, Ankit Madan, Peng Li, Benjamin Jones, Mansoor Saleh, Mary Jerome, Deborah Miley, Jennifer Keef, Francisco Robert. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology.
2019 03; 83(3):551-559. doi:
10.1007/s00280-018-3761-y. [PMID: 30603797] - Y Choi, D-H Lee, H K T Trinh, G-Y Ban, H-K Park, Y S Shin, S-H Kim, H-S Park. Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease.
Allergy.
2019 01; 74(1):78-88. doi:
10.1111/all.13458. [PMID: 29663427] - Makoto Hatano, Kazuhiro Tokuda, Yuka Kobayashi, Chiemi Yamashiro, Sho-Hei Uchi, Masaaki Kobayashi, Kazuhiro Kimura. Inhibitory effect of nintedanib on VEGF secretion in retinal pigment epithelial cells induced by exposure to a necrotic cell lysate.
PloS one.
2019; 14(8):e0218632. doi:
10.1371/journal.pone.0218632. [PMID: 31386668] - Luca Richeldi, Sophie Fletcher, Huzaifa Adamali, Nazia Chaudhuri, Sabrina Wiebe, Sven Wind, Kathrin Hohl, Andrew Baker, Rozsa Schlenker-Herceg, Susanne Stowasser, Toby M Maher. No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
The European respiratory journal.
2019 01; 53(1):. doi:
10.1183/13993003.01060-2018. [PMID: 30442716] - Hiroshi Ishii, Yoshiaki Kinoshita, Hisako Kushima, Nobuhiko Nagata, Kentaro Watanabe. The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis.
Chronic respiratory disease.
2019 Jan; 16(?):1479973119867945. doi:
10.1177/1479973119867945. [PMID: 31387379] - Anne M Filppula, Tiffany M Mustonen, Janne T Backman. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Basic & clinical pharmacology & toxicology.
2018 Dec; 123(6):739-748. doi:
10.1111/bcpt.13088. [PMID: 29956478] - Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou-Rouquette, Jeanne Chapron, Audrey Bellesoeur, Audrey Thomas-Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre, Michel Vidal, François Goldwasser, Benoît Blanchet. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Journal of pharmaceutical and biomedical analysis.
2018 Sep; 158(?):174-183. doi:
10.1016/j.jpba.2018.05.052. [PMID: 29883880] - Kristell Marzin, Gunther Kretschmar, Doreen Luedtke, Sandrine Kraemer, Raimund Kuelzer, Rozsa Schlenker-Herceg, Ulrike Schmid, David Schnell, Claudia Dallinger. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Journal of clinical pharmacology.
2018 03; 58(3):357-363. doi:
10.1002/jcph.1025. [PMID: 29106740] - Ulrike Schmid, Christiane Doege, Claudia Dallinger, Matthias Freiwald. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Pulmonary pharmacology & therapeutics.
2018 02; 48(?):136-143. doi:
10.1016/j.pupt.2017.11.004. [PMID: 29133080] - Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Wim A Wuyts. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
American journal of respiratory and critical care medicine.
2018 02; 197(3):356-363. doi:
10.1164/rccm.201706-1301oc. [PMID: 28889759] - Ulrike Schmid, Karl-Heinz Liesenfeld, Angele Fleury, Claudia Dallinger, Matthias Freiwald. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Cancer chemotherapy and pharmacology.
2018 01; 81(1):89-101. doi:
10.1007/s00280-017-3452-0. [PMID: 29119292] - Feng Liu, Li Wang, Hualin Qi, Jun Wang, Yi Wang, Wei Jiang, Liuqing Xu, Na Liu, Shougang Zhuang. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Clinical science (London, England : 1979).
2017 Aug; 131(16):2125-2143. doi:
10.1042/cs20170134. [PMID: 28646122] - Ali Saber Abdelhameed, Saima Nusrat, Sanjhi Paliwal, Masihuz Zaman, Nida Zaidi, Rizwan Hasan Khan. A multitechnique approach to probe the interaction of a therapeutic tyrosine kinase inhibitor nintedanib and bovine serum albumin.
Preparative biochemistry & biotechnology.
2017 Aug; 47(7):655-663. doi:
10.1080/10826068.2016.1275014. [PMID: 28045597] - Ibrahim Ismail, Sonu Nigam, Alan Parnham, Vinay Srinivasa. Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report.
Journal of medical case reports.
2017 Aug; 11(1):214. doi:
10.1186/s13256-017-1384-2. [PMID: 28779751] - Elena Tibaldi, Mario Angelo Pagano, Federica Frezzato, Valentina Trimarco, Monica Facco, Giuseppe Zagotto, Giovanni Ribaudo, Valeria Pavan, Luciana Bordin, Andrea Visentin, Francesca Zonta, Gianpietro Semenzato, Anna Maria Brunati, Livio Trentin. Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells.
Haematologica.
2017 08; 102(8):1401-1412. doi:
10.3324/haematol.2016.155747. [PMID: 28619847] - Razelle Kurzrock, David J Stewart. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Mar; 23(5):1137-1148. doi:
10.1158/1078-0432.ccr-16-1968. [PMID: 27940520] - Ganesh Raghu, Kevin K Brown, Harold R Collard, Vincent Cottin, Kevin F Gibson, Robert J Kaner, David J Lederer, Fernando J Martinez, Paul W Noble, Jin Woo Song, Athol U Wells, Timothy P M Whelan, Wim Wuyts, Emmanuel Moreau, Scott D Patterson, Victoria Smith, Selina Bayly, Jason W Chien, Qi Gong, Jenny J Zhang, Thomas G O'Riordan. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
The Lancet. Respiratory medicine.
2017 01; 5(1):22-32. doi:
10.1016/s2213-2600(16)30421-0. [PMID: 27939076] - Nasser H Hanna, Rolf Kaiser, Richard N Sullivan, Osvaldo Rudy Aren, Myung-Ju Ahn, Beatrice Tiangco, Isabelle Voccia, Joachim von Pawel, Vladimir Kovcin, Jason Agulnik, Birgit Gaschler-Markefski, José Barrueco, Patricia Sikken, Charles Schloss, Joo-Hang Kim. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Lung cancer (Amsterdam, Netherlands).
2016 12; 102(?):65-73. doi:
10.1016/j.lungcan.2016.10.011. [PMID: 27987591] - Paul Slobbe, Alex J Poot, Rianne Haumann, Robert C Schuit, Albert D Windhorst, Guus A M S van Dongen. Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Nuclear medicine and biology.
2016 10; 43(10):612-24. doi:
10.1016/j.nucmedbio.2016.07.003. [PMID: 27497236] - Li Wang, Feng-Chun Zhang, Xuan Zhang. Therapeutic advances for primary biliary cholangitis: the old and the new.
European journal of gastroenterology & hepatology.
2016 Jun; 28(6):615-21. doi:
10.1097/meg.0000000000000591. [PMID: 26862931] - Shweta Takyar, Jose Diaz, Manu Sehgal, Francisco Sapunar, Hardev Pandha. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Anti-cancer drugs.
2016 Jun; 27(5):383-97. doi:
10.1097/cad.0000000000000335. [PMID: 26886011] - J Guiot, B Bondue, M Henket, J L Corhay, R Louis. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.
BMC pulmonary medicine.
2016 May; 16(1):86. doi:
10.1186/s12890-016-0249-6. [PMID: 27215343] - Parvez Alam, Ali S Abdelhameed, Ravi Kant Rajpoot, Rizwan Hasan Khan. Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin.
Journal of photochemistry and photobiology. B, Biology.
2016 Apr; 157(?):70-6. doi:
10.1016/j.jphotobiol.2016.02.009. [PMID: 26894847] - Dan Lin, Li-man Qiao, Yu-niao Zhang, Yuan Liu, Xin-she Liu. Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2016 Jan; 117(?):173-7. doi:
10.1016/j.jpba.2015.08.024. [PMID: 26355771] - Manuela Funke-Chambour, Thomas Geiser. [Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis].
Therapeutische Umschau. Revue therapeutique.
2016; 73(1):25-9. doi:
10.1024/0040-5930/a000751. [PMID: 26884217] - Cong Xue, Ying Tian, Jing Zhang, Yuanyuan Zhao, Jianhua Zhan, Wenfeng Fang, Li Zhang. Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.
Drug design, development and therapy.
2016; 10(?):1173-80. doi:
10.2147/dddt.s96634. [PMID: 27042009] - T Eisen, A-B Loembé, Y Shparyk, N MacLeod, R J Jones, M Mazurkiewicz, G Temple, H Dressler, I Bondarenko. A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
British journal of cancer.
2015 Oct; 113(8):1140-7. doi:
10.1038/bjc.2015.313. [PMID: 26448178] - Xiao-wei Xu, Xin-juan Su, Yu-niao Zhang, Xiao-kang Zheng, Peng-fei Lv, Jie Hu. Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS/MS and its application in drug tissue distribution study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2015 Oct; 1002(?):239-44. doi:
10.1016/j.jchromb.2015.08.032. [PMID: 26342166] - Tomoo Kishaba. Practical management of Idiopathic Pulmonary Fibrosis.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
2015 Jul; 32(2):90-8. doi:
NULL. [PMID: 26278687] - Takashi Ogura, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Yasuhiro Kondoh, Yoshinori Hasegawa, Masashi Bando, Shinji Abe, Yoshiro Mochizuki, Kingo Chida, Matthias Klüglich, Tsuyoshi Fujimoto, Kotaro Okazaki, Yusuke Tadayasu, Wataru Sakamoto, Yukihiko Sugiyama. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
The European respiratory journal.
2015 May; 45(5):1382-92. doi:
10.1183/09031936.00198013. [PMID: 25504994] - Klaus Mross, Martin Büchert, Annette Frost, Michael Medinger, Peter Stopfer, Matus Studeny, Rolf Kaiser. Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.
BMC cancer.
2014 Jul; 14(?):510. doi:
10.1186/1471-2407-14-510. [PMID: 25012508] - Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue, Dong Soon Kim, Martin Kolb, Andrew G Nicholson, Paul W Noble, Moisés Selman, Hiroyuki Taniguchi, Michèle Brun, Florence Le Maulf, Mannaïg Girard, Susanne Stowasser, Rozsa Schlenker-Herceg, Bernd Disse, Harold R Collard. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
The New England journal of medicine.
2014 May; 370(22):2071-82. doi:
10.1056/nejmoa1402584. [PMID: 24836310] - Tim Eisen, Yaroslav Shparyk, Nicholas Macleod, Robert Jones, Gudrun Wallenstein, Graham Temple, Yasser Khder, Claudia Dallinger, Matus Studeny, Arsene-Bienvenu Loembe, Igor Bondarenko. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Investigational new drugs.
2013 Oct; 31(5):1283-93. doi:
10.1007/s10637-013-9962-7. [PMID: 23625328] - Xiaoping Cai, S Ben Freedman, Paul K Witting. Serum amyloid A stimulates cultured endothelial cells to migrate and proliferate: inhibition by the multikinase inhibitor BIBF1120.
Clinical and experimental pharmacology & physiology.
2013 Sep; 40(9):662-70. doi:
10.1111/1440-1681.12148. [PMID: 23819722] - G Bousquet, J Alexandre, C Le Tourneau, F Goldwasser, S Faivre, H de Mont-Serrat, R Kaiser, J L Misset, E Raymond. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
British journal of cancer.
2011 Nov; 105(11):1640-5. doi:
10.1038/bjc.2011.440. [PMID: 22027711] - Peter Stopfer, Karin Rathgen, Daniel Bischoff, Silke Lüdtke, Kristell Marzin, Rolf Kaiser, Klaus Wagner, Thomas Ebner. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
Xenobiotica; the fate of foreign compounds in biological systems.
2011 Apr; 41(4):297-311. doi:
10.3109/00498254.2010.545452. [PMID: 21204634] - Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh, Wataru Okamoto, Masaki Miyazaki, Ryotaro Morinaga, Shinya Ueda, Masaaki Terashima, Asuka Tsuya, Akiko Sarashina, Koichi Konishi, Tokuzo Arao, Kazuto Nishio, Rolf Kaiser, Kazuhiko Nakagawa. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Molecular cancer therapeutics.
2010 Oct; 9(10):2825-33. doi:
10.1158/1535-7163.mct-10-0379. [PMID: 20688946]
